Anemia Management News

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis discusses exciting new agents in the pipeline which may have a ‘significant impact' on how physicians approach patients with CKD.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, spoke with Healio on the relationship between anemia and quality of life in patients with chronic kidney disease.

There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year.1

Analyses of data from two clinical trials and a real-world study revealed an increased risk for anemia among adults with type 2 diabetes prescribed metformin.

Akebia Therapeutics Inc. said its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat reached primary and key secondary efficacy endpoints in phase 3 PRO2TECT cardiovascular outcomes studies.

In patients with anemia who present with MI, a restrictive blood transfusion strategy was noninferior to liberal transfusion for preventing major adverse CV events at 30 days, according to results of the REALITY trial.

Ferric citrate may be more effective than ferrous sulfate for treating iron deficiency in patients with chronic kidney disease, according to this study.

An analysis of published studies showed relief of fatigue for patients with chronic kidney disease and anemia when treatment with erythropoietin stimulating agents led to hemoglobin levels higher than currently recommended targets.

Akebia Therapeutics Inc. recently announced that Japan has approved vadadustat for the treatment of anemia due to chronic kidney disease. This marks the first regulatory approval of the drug, according to a company press release.

The European Medicines Agency has accepted a marketing authorization application from Astellas Pharmaceuticals for its hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat for the treatment of anemia in adult patients with chronic kidney disease.